Aytu BioPharma Inc./$AYTU
1D1W1MYTD1Y5YMAX
About Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
- Ticker
- $AYTU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 83
- Headquarters
- Denver, United States
- Website
- aytubio.com
AYTU Metrics
BasicAdvanced
$24M
-
-$3.71
0.25
-
Price and volume
Market cap
$24M
Beta
0.25
52-week high
$3.07
52-week low
$1.65
Average daily volume
29K
Financial strength
Current ratio
1.123
Quick ratio
0.854
Long term debt to equity
29.787
Total debt to equity
65.27
Interest coverage (TTM)
-3.08%
Profitability
EBITDA (TTM)
-2.625
Gross margin (TTM)
64.78%
Net profit margin (TTM)
-60.17%
Operating margin (TTM)
-12.19%
Effective tax rate (TTM)
-1.33%
Revenue per employee (TTM)
$680,000
Management effectiveness
Return on assets (TTM)
-3.66%
Return on equity (TTM)
-97.42%
Valuation
Price to revenue (TTM)
0.364
Price to book
0.68
Price to tangible book (TTM)
-3.27
Price to free cash flow (TTM)
-15.182
Free cash flow yield (TTM)
-6.59%
Free cash flow per share (TTM)
-0.148
Growth
Revenue change (TTM)
-14.04%
Earnings per share change (TTM)
344.72%
3-year revenue growth (CAGR)
-18.39%
10-year revenue growth (CAGR)
41.12%
3-year earnings per share growth (CAGR)
-30.55%
AYTU News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.